SCHEMBL4176165

SCHEMBL4176165

COc1ccccc1C1CCCN1C(=O)c1csc(NS(=O)(=O)c2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.49
SCD5 Q86SK9 3/20 0.48
TRPC3 Q13507 3/20 0.48
TRPC6 Q9Y210 3/20 0.48
HSP90AA1 P07900 1/20 0.48
HSP90AB1 P08238 1/20 0.48
ROCK2 O75116 1/20 0.45
KDM1A O60341 1/20 0.42
SHMT2 P34897 1/20 0.42
TRPV1 Q8NER1 2/20 0.41
MCOLN2 Q8IZK6 2/20 0.41
MCOLN3 Q8TDD5 2/20 0.41
MCOLN1 Q9GZU1 2/20 0.41
PPIB P23284 2/20 0.41
PPID Q08752 1/20 0.41
PPIG Q13427 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4179996 0.86 SCN9A (0.51) SCN9ASCD5TRPC3TRPC6ROCK2
SCHEMBL4177686 0.86 SCN9A (0.51) SCN9ATRPC3TRPC6HSP90AA1HSP90AB1
SCHEMBL4172599 0.85 TRPC3 (0.61) SCN9ASCD5TRPC3TRPC6TRPV1
SCHEMBL4176998 0.84 TRPC3 (0.52) SCN9ASCD5TRPC3TRPC6ROCK2
SCHEMBL4177448 0.83 TRPC3 (0.54) SCN9ATRPC3TRPC6HSP90AA1HSP90AB1
SCHEMBL4165105 0.82 TRPC3 (0.66) SCN9ASCD5TRPC3TRPC6ALDH1A1
SCHEMBL4170692 0.82 TRPC3 (0.65) SCN9ASCD5TRPC3TRPC6ALDH1A1
SCHEMBL4173881 0.81 TRPC3 (0.56) SCN9ASCD5TRPC3TRPC6ROCK2
SCHEMBL4180201 0.81 SCN9A (0.49) SCN9ASCD5TRPC3TRPC6KDM1A
SCHEMBL4165060 0.81 TRPC3 (0.55) SCN9ASCD5TRPC3TRPC6ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN9A 51/4885SCD5 1301/4885TRPC3 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.